Spots Global Cancer Trial Database for hepatocellular carcinoma
Every month we try and update this database with for hepatocellular carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Pressure-enabled Delivery in Radioembolization (TriNav Study) | NCT05128032 | Liver Cancer Hepatocellular ... Metastatic Colo... | Standard microc... PEDD device | 18 Years - | Massachusetts General Hospital | |
| Cryoablation Combined With Camrelizumab and Apatinib in Advanced Hepatocellular Carcinoma | NCT04724226 | Hepatocellular ... | Camrelizumab; A... | 18 Years - 70 Years | Sun Yat-sen University | |
| HepatoPredict Prognostic Tool for the Decision of Liver Transplant in Hepatocellular Carcinoma | NCT04499833 | Hepatocellular ... Recurrence Tumo... | liver transplan... | 18 Years - 70 Years | Centro Hospitalar de Lisboa Central | |
| Trial of Transcatheter Arterial Chemoembolization (TACE) With Sorafenib for Locally Advanced Hepatocellular Carcinoma (HCC) | NCT01170104 | Hepatocellular ... | Sorafenib TACE (Transcath... | 18 Years - | Chung-Ang University | |
| Ate-Bev Early Response Prediction Model in Advanced HCC | NCT05763277 | Hepatocellular ... Atezolizumab-be... Response Evalua... | Early response ... | 18 Years - 80 Years | Seoul National University Hospital | |
| Evaluation of Stereotactic Body Radiotherapy as a Bridge Therapy for Hepatocellular Carcinoma Patients Enlisted for Liver Transplantation | NCT06218420 | Hepatocellular ... | Stereotactic Bo... | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| Radiofrequency Ablation Versus Liver Resection for Elderly Patients With Hepatocellular Carcinoma (HCC) Within the Milan Criteria | NCT01570075 | Hepatocellular ... | HR RFA | 65 Years - 85 Years | Sun Yat-sen University | |
| The Impact on Survival of Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Beyond Milan Criteria BCLC Stage A/B Hepatocellular Carcinoma Who Underwent Hepatectomy | NCT03851913 | Hepatocellular ... | TAI | 18 Years - 75 Years | Sun Yat-sen University | |
| Enumeration and Function Analysis of Treg Cells in Peripheral Blood of HCC Patients Before and After Ablation Therapy | NCT01668381 | Hepatocellular ... | radiofrequency ... | 18 Years - 80 Years | First Affiliated Hospital, Sun Yat-Sen University | |
| DEB-TACE for Hepatocellular Carcinoma | NCT02748161 | Hepatocellular ... | DEB-TACE | 18 Years - | SurefireMedical | |
| Stereotactic Body Radiation Therapy (SBRT) vs Trans-Arterial Chemoembolization (TACE) as Bridge to Transplant | NCT03960008 | Hepatocellular ... HCC | Stereotactic Bo... Trans-Arterial ... Doxorubin | 18 Years - | Lahey Clinic | |
| Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular Carcinoma | NCT03841201 | Advanced Hepato... | Lenvatinib Nivolumab | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| Characterization of Baseline Biomarker Variability in Participants With Hepatocellular Carcinoma (MK-0000-215) | NCT01521780 | Hepatocellular ... | MRI Pathology Blood Samples Blood Samples | 18 Years - | Merck Sharp & Dohme LLC | |
| TACE Combined With Penpulimab and Anlotinib for Advanced HCC | NCT05344924 | Hepatocellular ... | TACE+penpulimab... | 18 Years - 80 Years | Zhongda Hospital | |
| A Dose Escalation Trial of Radiation Therapy (RT) for Hepatocellular Carcinoma (HCC) | NCT00960167 | Hepatocellular ... | 3DCRT or IMRT | 18 Years - 70 Years | National Taiwan University Hospital | |
| Dose Escalation Trial of Tefinostat for Cancer Associated Inflamation in Hepatocellular Carcinoma (HCC) | NCT02759601 | Hepatocellular ... | Tefinostat | 18 Years - | Queen Mary University of London | |
| A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma | NCT03519997 | Hepatocellular ... | Pembrolizumab Bavituximab | 18 Years - | University of Texas Southwestern Medical Center | |
| A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203) | NCT05104567 | Oesophageal Squ... Gastric Cancer Hepatocellular ... Colorectal Canc... Oesophageal Ade... | THOR-707 Pembrolizumab Cetuximab | 18 Years - | Sanofi | |
| CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma | NCT05257590 | Hepatocellular ... Advanced Cancer | Nivolumab Injec... CVM-1118 | 18 Years - | TaiRx, Inc. | |
| Phase II Trial of Carbon-ion Radiotherapy Combined With GM-CSF for the Treatment of Hepatocellular Carcinoma | NCT02946138 | Hepatocellular ... | carbon-ion radi... | 18 Years - 80 Years | Shanghai Proton and Heavy Ion Center | |
| To Evaluate the Efficacy and Safety of (18F-FCH) Comparing With (18F-FDG) for Detecting Hepatocellular Carcinoma | NCT02074202 | Hepatocellular ... Liver Disease | 18F- fluorochol... 18F- fluorodeox... | 20 Years - 80 Years | National Taiwan University Hospital | |
| HAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular Carcinama | NCT04627363 | Hepatocellular ... Bevacizumab Liver Neoplasms Toripalimab Oxaliplatin | Hepatic arteria... Bevacizumab Toripalimab | 18 Years - 75 Years | Sun Yat-sen University | |
| Yang Yin Fu Zheng Therapy in HBV Associated Hepatocellular Carcinoma | NCT02927626 | Hepatocellular ... | Yang Yin Fu Zhe... Routine medical... | 18 Years - 75 Years | Beijing Ditan Hospital | |
| A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours | NCT02423239 | Hepatocellular ... Pancreatic Canc... | Dexanabinol Sorafenib Nab-paclitaxel Gemcitabine | 18 Years - | e-Therapeutics PLC | |
| Transarterial Chemoembolisation Plus Bevacizumab for Treatment of Hepatocellular Carcinoma | NCT00280007 | Hepatocellular ... | bevacizumab | 18 Years - 85 Years | Medical University of Vienna | |
| Cabozantinib Treatment in a Phase II Study for Patients With Hepatocellular Carcinoma (HCC) Refractory to PD-1 Inhibitors | NCT04767906 | Hepatocellular ... | Cabozantinib | 18 Years - | University of Leipzig | |
| Comparison Between Unilateral Versus Bilateral Stenting for Malignant Hilar Biliary Obstruction to Use a LCD Stent | NCT01875549 | Obstruction of ... Cholangiocarcin... Hepatocellular ... Malignant Lymph... Gall Bladder Ca... | stent insertion Endoscopic retr... | 18 Years - | Samsung Medical Center | |
| Phase 2 Study of Sorafenib Plus HAIC of FOLFOX vs. Sorafenib Plus HAIC of OXA for Advanced HCC | NCT03812770 | Hepatocellular ... | Sorafenib HAIC of FOLFOX HAIC of OXA | 18 Years - 75 Years | Sun Yat-sen University | |
| Study to Compare Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (HCC) | NCT01135056 | Hepatocellular ... | SIR-Spheres Sorafenib tosyl... | 18 Years - | Singapore General Hospital | |
| Prospective Post Y90 Liver Hypertrophy | NCT02783261 | Hepatocellular ... Liver Hypertrop... | CT volumetric m... | 21 Years - 99 Years | Singapore General Hospital | |
| Study of NP-101 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Undergoing Y-90 Treatment | NCT06217094 | Hepatocellular ... | NP-101 (3 g) NP-101 (4.8 g) NP-101 (6 g) | 18 Years - 99 Years | University of Florida | |
| Study of Factors Predicting Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma (HCC) | NCT01198704 | Hepatocellular ... Liver Cirrhosis Evidence of Liv... | search of facto... | 18 Years - 70 Years | Assistance Publique - Hôpitaux de Paris | |
| the Efficacy and Safety of Ginsenoside Rg3 Capsule in Prevention of Postoperative Recurrence of Hepatocellular Carcinoma | NCT01717066 | Stage I Hepatoc... Stage II Hepato... | the ginsenoside... Placebo | 18 Years - 75 Years | Eastern Hepatobiliary Surgery Hospital | |
| Ambispective Cohort Study of Precision Medicine for Primary Hepatobiliary Cancer Based on Next-generation Sequencing | NCT05520788 | Hepatocellular ... Biliary Tract C... | precise medicin... | 18 Years - | Tongji Hospital | |
| TACE+Tilelizumab+Sorafenib in the Treatment of BCLC Stage C HCC | NCT04992143 | BCLC Stage C He... | TACE Tilelizumab Sorafenib | 18 Years - | First Affiliated Hospital of Zhejiang University | |
| Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma | NCT02191878 | Hepatocellular ... Hepatoma Liver Cancer, A... Liver Cell Carc... | TKM-080301 | 18 Years - | Arbutus Biopharma Corporation | |
| A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer | NCT05394259 | Pancreatic Canc... Breast Cancer Hepatocellular ... | Piflufolastat F... | 18 Years - | M.D. Anderson Cancer Center | |
| Artificial Intelligence and Hepatocellular Carcinoma | NCT05637788 | HCC | CT Scan Radiomi... | 18 Years - | Humanitas Clinical and Research Center | |
| HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCC | NCT05029973 | Hepatocellular ... | HAIC Sintilimab Bevacizumab Bio... | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Combined Ipsilateral Liver Lobe Devascularization and Alcohol Treatment of the Large Hepatocellular Carcinoma | NCT03138044 | Hepatocellular ... | Combined Treatm... | 15 Years - 75 Years | The National Ribat University | |
| Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery | NCT02174575 | Hepatocellular ... Hepatoma Cholangiocarcin... Gallbladder Neo... | Sevoflurane Desflurane | 20 Years - | Tokyo Medical and Dental University | |
| Phase II of Lenvatinib Plus Toripalimab for Advanced HCC | NCT03919383 | Hepatocellular ... | Lenvatinib Toripalimab | 18 Years - 75 Years | Sun Yat-sen University | |
| Study of Pegylated Human Recombinant Arginase for Liver Cancer (BCT-100-002) | NCT01092091 | Neoplasm Hepatocellular ... | Pegylated Recom... | 18 Years - 75 Years | Bio-Cancer Treatment International Limited | |
| Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC) | NCT00617981 | Hepatocellular ... | ThermoDox 5% Dextrose Sol... | 18 Years - | Imunon | |
| Contrast-enhanced Ultrasound With Perfluorobutane and Sulfur Hexafluoride for Hepatocellular Carcinoma | NCT04847726 | Hepatocellular ... | contrast enhanc... Dynamic CT Liver MRI | 18 Years - | Seoul National University Hospital | |
| Radial Versus Femoral Access for Superselective Embolization of Hepatocellular Carcinoma | NCT03807947 | Hepatocellular ... Hepatocellular ... | Radial TAE - Bl... Transfemoral TA... | 40 Years - 90 Years | Humanitas Clinical and Research Center | |
| A Study of HFB301001 in Adult Patients With Advanced Solid Tumors | NCT05229601 | Soft Tissue Sar... Renal Cell Carc... Uterine Carcino... Hepatocellular ... Head and Neck S... Melanoma | HFB301001 | 18 Years - | HiFiBiO Therapeutics | |
| The Impact on Hepatic Recurrence After Adjuvant Chemotherapy With Intraarterial Infusion of Idarubicin-Lipiodol | NCT04178642 | Hepatocellular ... | percutaneous de... Percutaneous de... | 18 Years - 80 Years | University Hospital, Montpellier | |
| Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer | NCT03812289 | Hepatocellular ... | Quality-of-Life... Questionnaire A... Stereotactic Bo... | 18 Years - | OHSU Knight Cancer Institute | |
| Transarterial Chemoembolization (TACE) Versus TACE Plus Stereotactic Body Radiation Therapy (SBRT) in Liver Carcinoma | NCT03895359 | Hepatocellular ... | Stereotactic Bo... Transarterial C... | 18 Years - | Lawson Health Research Institute | |
| LDE225 in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A/B7 Cirrhosis | NCT02151864 | Hepatocellular ... Cirrhosis | LDE225 | 18 Years - | University of California, San Diego | |
| Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial for First-line Treatment of Hepatocellular Carcinoma | NCT06364787 | Hepatocellular ... | γδ T cells Targeted drugs PD-1 monoclonal... | 18 Years - 75 Years | Beijing 302 Hospital | |
| Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma | NCT02415036 | Hepatocellular ... Intrahepatic Ch... | Delcath Hepatic... Melphalan | 18 Years - | Delcath Systems Inc. | |
| Ablation Combined With PD-1 in HCC: Phase II Study | NCT04652440 | Hepatocellular ... | PD-1 monoclonal... Radiofequencey ... | 18 Years - 75 Years | Sun Yat-sen University | |
| Relevance of Sarcopenia in Advanced Liver Disease | NCT05502198 | Liver Cirrhosis Hepatocellular ... Sarcopenia Portal Hyperten... | 18 Years - | Linkoeping University | ||
| Substudy: Interconnection of Arterial Tumor Feeders Through Tumor Sinusoid in HCC | NCT04641637 | Hepatocellular ... | TACE | 18 Years - | Chinese University of Hong Kong | |
| Antiviral Therapy for Patients With Liver Cancer After Surgery | NCT05466565 | Hepatocellular ... | 18 Years - 65 Years | Xiangya Hospital of Central South University | ||
| Study of GNS561 in Patients With Liver Cancer | NCT03316222 | Hepatocellular ... Cholangiocarcin... | GNS561 | 18 Years - | Genoscience Pharma | |
| the Effect of Different Oxaliplatin Dose in Transarterial Infusion (TAI) in Unresectable Hepatocellular Carcinoma | NCT03777475 | Hepatocellular ... | transarterial i... | 18 Years - 75 Years | Sun Yat-sen University | |
| A Survey for Factors That Influence Postoperative Treatment Decision-making for Hepatocellular Carcinoma | NCT04239781 | Hepatocellular ... | 18 Years - | Shanghai Zhongshan Hospital | ||
| Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients | NCT03916627 | Non-small Cell ... Hepatocellular ... Head and Neck S... | cemiplimab Platinum Double... fianlimab | 18 Years - | Regeneron Pharmaceuticals | |
| Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment | NCT01492127 | Hepatocellular ... Cirrhosis | Blood test | 18 Years - | University Hospital, Montpellier | |
| Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms | NCT01640522 | Hepatocellular ... Primary Liver C... Bile Duct Cance... Pancreatic Canc... Gallbladder Can... Colorectal Carc... Liver Metastase... | Collaborative C... Enhanced usual ... | 18 Years - | University of Pittsburgh | |
| Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors | NCT02867592 | Adrenal Cortica... Alveolar Soft P... Central Nervous... Childhood Clear... Clear Cell Sarc... Ewing Sarcoma Hepatoblastoma Hepatocellular ... Osteosarcoma Recurrent Adren... Recurrent Alveo... Recurrent Clear... Recurrent Ewing... Recurrent Hepat... Recurrent Hepat... Recurrent Kidne... Recurrent Malig... Recurrent Osteo... Recurrent Prima... Recurrent Renal... Recurrent Rhabd... Recurrent Soft ... Recurrent Thyro... Refractory Adre... Refractory Alve... Refractory Clea... Refractory Ewin... Refractory Hepa... Refractory Hepa... Refractory Mali... Refractory Oste... Refractory Prim... Refractory Prim... Refractory Rena... Refractory Rhab... Refractory Soft... Refractory Thyr... Refractory Wilm... Renal Cell Carc... Rhabdomyosarcom... Soft Tissue Sar... Solid Neoplasm Thyroid Gland M... Wilms Tumor | Cabozantinib Cabozantinib S-... Pharmacological... | 2 Years - 30 Years | National Cancer Institute (NCI) | |
| Combined Radiotherapy and Sorafenib in Patients With Hepatoma | NCT01319942 | Hepatocellular ... | Radiotherapy co... | 20 Years - 69 Years | China Medical University Hospital | |
| Effects of Antiviral Therapy on Patients With HBV-related HCC | NCT05406089 | Hepatocellular ... Hepatitis B Vir... Survival | Medication hist... | 20 Years - 70 Years | First Affiliated Hospital Xi'an Jiaotong University | |
| Dose-Escalation Study Evaluating the Safety and Pharmacokinetics of Artesunate in Patients With Hepatocellular Carcinoma | NCT02304289 | Hepatocellular ... | Artesunate | 18 Years - | University Hospital, Ghent | |
| Multiple Antigen Specific Cell Therapy (MASCT) for Hepatocellular Carcinoma(HCC) Patients After Radical Resection or Radio Frequency Ablation(RFA). | NCT02026362 | Hepatocellular ... | MASCT:Multiple ... The foundation ... | 20 Years - 70 Years | HRYZ Biotech Co. | |
| Study of Apatinib Combined With TACE in Advance Hepatocellular Carcinoma | NCT03398122 | Hepatocellular ... | TACE Apatinib | 18 Years - 70 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T | NCT05760599 | Hepatocellular ... | Candonilimab Bevacizumab | 18 Years - 75 Years | Sun Yat-sen University | |
| TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers | NCT03829436 | Hepatocellular ... Metastatic Cast... Renal Cell Carc... Non-small Cell ... Colorectal Canc... Squamous Cell C... Triple-Negative... Urothelial Carc... Cholangiocarcin... GastroEsophagea... Pancreatic Canc... Sarcoma | Part 1 TPST-112... Part 2 TPST-112... Part 3 TPST-112... Part 4 TPST-112... | 18 Years - | Tempest Therapeutics | |
| Resection And Partial LIver Transplantation With Delayed Hepatectomy for Hepatocellular Carcinoma | NCT05971628 | Hepatocellular ... | RAPID procedure | 18 Years - 68 Years | Assistance Publique - Hôpitaux de Paris | |
| A Phase I Clinical Study on a New Oral Pentamidine Formulation in Hepatocellular Carcinoma | NCT02210182 | Hepatocellular ... | Oral Pentamidin... Placebo | 18 Years - 80 Years | Oncozyme Pharma Inc. | |
| Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | NCT03190174 | Ewing Sarcoma PEComa Epithelioid Sar... Desmoid Tumor Chordoma Non Small Cell ... Urothelial Carc... Melanoma Renal Cell Carc... Squamous Cell C... Hepatocellular ... Classical Hodgk... Colorectal Canc... MTOR Activating... | Nab-Rapamycin Nivolumab | 12 Years - | Sarcoma Oncology Research Center, LLC | |
| A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma | NCT05320692 | Hepatocellular ... | TACE+Camrelizum... TACE | 18 Years - | Jiangsu HengRui Medicine Co., Ltd. | |
| Phase 2 Study of ADI-PEG 20 Plus Lenvatinib Treatment in Subjects With Unresectable Hepatocellular Carcinoma | NCT06034977 | Hepatocellular ... | ADI-PEG20 | 18 Years - | Chang Gung Memorial Hospital | |
| Sorafenib in Hepatocellular Carcinoma Clinical Practice in Italy | NCT01539681 | Hepatocellular ... | Sorafenib (Nexa... | 18 Years - | Bayer | |
| IMA970A Plus CV8102 in Very Early, Early and Intermediate Stage Hepatocellular Carcinoma Patients | NCT03203005 | Hepatocellular ... | IMA970A plus CV... | 18 Years - | National Cancer Institute, Naples | |
| A Phase 1/2 Study of BA3071 as Monotherapy and in Combination With a PD-1 Blocking Antibody in Patients With Advanced Solid Tumors | NCT05180799 | Solid Tumor, Ad... NSCLC Urothelial Carc... Gastric Cancer Small Cell Lung... Hepatocellular ... Cervical Carcin... Melanoma Renal Cell Carc... Carcinoma | BA3071 Nivolumab Pembrolizumab | 18 Years - | BioAtla, Inc. | |
| Immunotherapy of Hepatocellular Carcinoma With Gamma Delta T Cells | NCT00562666 | Hepatocellular ... | T gamma delta l... | 18 Years - | Rennes University Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
